Tina Bocker Edmonston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tina Bocker Edmonston has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Anthony Pompetti
1 shared publication- Catherine Kendall Major
Leukemia Department, MD Anderson Cancer Center, Lakeland, TN
1 shared publication - Catherine Skibiel
Department of Pathology and Laboratory Medicine , Cooper University Health Care , Camden , New Jersey , USA , lhsc.on.ca
1 shared publication Chiara J Cocelli
Cooper Medical School of Rowan University , Camden, NJ
1 shared publication- Christopher Moran
Department of Internal Medicine , Rutgers Health Robert Wood Johnson Medical School , New Brunswick , New Jersey , USA
1 shared publication - Congli Wang1 shared publication
Latest Publications
- Open Access
- 25 June 2026
- Published by Elsevier in SSRN Electronic Journal
Targeting Cellular Pseudo-Senescence to Overcome PARP inhibitors Resistance in BRCA1-Mutated Breast Cancer
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a mainstay therapy for homologous recombination (HR)-deficient cancers; however, resistance remains a major clinical challenge. Previously, through a genome wide CRISPR screen, we identified ZNF251 haploinsufficiency as a novel driver of PARPi resistance. In BRCA1-mutant (BRCA1mut) cells, ZNF251 deficiency led to HR hyperactivation, conferring PARPi resistance that could be reversed by RAD51 inhibition. In this study, we further show that ZNF251 deficiency induces replication stress and a pseudo-senescence state, in which cells exhibit molecular and phenotypic markers of senescence while retaining proliferative capacity. Because senomorphic and senolytic therapies can target senescent cells, we tested whether these approaches could overcome PARPi resistance in ZNF251-deficient breast cancer cells. Critically, targeting this senescence-like state with either senomorphic agents, such as cytokine inhibitors, or senolytic agents, such as BCL-2 and BCL-XL inhibitors, overcame PARPi resistance ex vivo and in vivo. Importantly, pseudo-senescence was also observed in other PARPi-resistant contexts driven by HR hyperactivation, including 53BP1- and Shieldin-mutant cells, suggesting that it may represent a broader mechanism underlying PARPi resistance in breast cancer. Furthermore, in two olaparib-resistant, BRCA-mutant triple-negative breast cancer organoid models, treatment with DT2216, a BCL-XL–targeting PROTAC, sensitized both models to olaparib. Together, our work defines a novel pathway linking HR hyperactivation, replication stress, and pseudo-senescence, and positions both senomorphic and senolytic therapies as promising strategies to overcome PARPi resistance in BRCA1mut breast cancer.
- 25 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTargeting Cellular Pseudo-Senescence to Overcome PARP inhibitors Resistance in BRCA1-Mutated Breast Cancer
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a mainstay therapy for homologous recombination (HR)-deficient cancers; however, resistance remains a major clinical challenge. Previously, through a genome wide CRISPR screen, we identified ZNF251 haploinsufficiency as a novel driver of PARPi resistance. In BRCA1-mutant (BRCA1mut) cells, ZNF251 deficiency led to HR hyperactivation, conferring PARPi resistance that could be reversed by RAD51 inhibition. In this study, we further show that ZNF251 deficiency induces replication stress and a pseudo-senescence state, in which cells exhibit molecular and phenotypic markers of senescence while retaining proliferative capacity. Because senomorphic and senolytic therapies can target senescent cells, we tested whether these approaches could overcome PARPi resistance in ZNF251-deficient breast cancer cells. Critically, targeting this senescence-like state with either senomorphic agents, such as cytokine inhibitors, or senolytic agents, such as BCL-2 and BCL-XL inhibitors, overcame PARPi resistance ex vivo and in vivo. Importantly, pseudo-senescence was also observed in other PARPi-resistant contexts driven by HR hyperactivation, including 53BP1- and Shieldin-mutant cells, suggesting that it may represent a broader mechanism underlying PARPi resistance in breast cancer. Furthermore, in two olaparib-resistant, BRCA-mutant triple-negative breast cancer organoid models, treatment with DT2216, a BCL-XL–targeting PROTAC, sensitized both models to olaparib. Together, our work defines a novel pathway linking HR hyperactivation, replication stress, and pseudo-senescence, and positions both senomorphic and senolytic therapies as promising strategies to overcome PARPi resistance in BRCA1mut breast cancer.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Urology
- Vol. 2026 (1) , 4462826
Adult Granulosa Cell Tumor With Low‐Level Amplifications of JAK2 , ERBB3 , CDK4 , and MDM2 : A Rare Testicular Tumor
Testicular adult granulosa cell tumors (AGCTs) are exceptionally rare neoplasms that are thought to be the male counterpart of ovarian granulosa cell tumors (GCT). Here, we present a 50‐year‐old African American male who initially presented with right testicular pain and swelling, with ultrasound revealing a 2.0‐cm heterogeneous hypoechoic lesion along the upper pole/interpolar right testicle with internal vascularity. Microscopic examination was consistent with AGCT, demonstrating monomorphic cells with elongated nuclei containing numerous small grooves, resembling ovarian granulosa cells, and scant cytoplasm arranged in trabeculae and sheets. Immunohistochemical stains of the tumor were positive for inhibin, vimentin, and weakly positive for calretinin, S100, and Ki67 (10%). Next Generation Sequencing (NGS) showed low‐level amplifications of JAK2 , ERBB3 , CDK4 , and MDM2 . No gene fusions or mutations were identified. The patient underwent a radical orchiectomy and remains alive and disease‐free at 42 months following diagnosis.
- 1 January 2026
- Published by Wiley in Case Reports in Urology
- Vol. 2026 (1) , 4462826
Open AccessAdult Granulosa Cell Tumor With Low‐Level Amplifications of JAK2 , ERBB3 , CDK4 , and MDM2 : A Rare Testicular Tumor
Testicular adult granulosa cell tumors (AGCTs) are exceptionally rare neoplasms that are thought to be the male counterpart of ovarian granulosa cell tumors (GCT). Here, we present a 50‐year‐old African American male who initially presented with right testicular pain and swelling, with ultrasound revealing a 2.0‐cm heterogeneous hypoechoic lesion along the upper pole/interpolar right testicle with internal vascularity. Microscopic examination was consistent with AGCT, demonstrating monomorphic cells with elongated nuclei containing numerous small grooves, resembling ovarian granulosa cells, and scant cytoplasm arranged in trabeculae and sheets. Immunohistochemical stains of the tumor were positive for inhibin, vimentin, and weakly positive for calretinin, S100, and Ki67 (10%). Next Generation Sequencing (NGS) showed low‐level amplifications of JAK2 , ERBB3 , CDK4 , and MDM2 . No gene fusions or mutations were identified. The patient underwent a radical orchiectomy and remains alive and disease‐free at 42 months following diagnosis.
- 6 October 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (5) , 813-819
Implementation of a next-generation sequencing and PD-L1 immunohistochemistry reflex testing protocol for non–small cell lung cancers improves turnaround time
Objective: Targeted therapy in non–small cell lung cancer (NSCLC) is now often included as first-line treatment in the neoadjuvant and adjuvant settings. Delays in optimizing treatments based on biomarker status can affect outcomes. Therefore, we assessed the turnaround time (TAT) of reflex biomarker testing for all NSCLCs clinical stage 1B and greater. Methods: A next-generation sequencing (NGS) and PD-L1 immunohistochemistry reflex protocol for NSCLC clinical stage 1B and greater was implemented. Turnaround time intervals between procedure date, pathology sign-out, date received in the molecular laboratory, and date of NGS sign-out were calculated. Median and IQR of each interval before and after implementation of the reflex protocol were calculated and compared using the Mann-Whitney U test. Results: In total, 492 lung cancer NGS cases were identified, 351 before and 141 after implementation of the reflex protocol. The prereflex cases, after exclusion of biomarker testing ordered on older blocks and outside consults (n = 165), demonstrated a 22-day median time from procedure to NGS sign-out (range, 11-70 days; IQR, 9; mean, 24 days), compared to a 20-day median time (range, 13-54 days; IQR, 4.5; mean, 21 days) postimplementation (n = 120) (P < .000103). Conclusions: Reduction in median TAT from procedure to NGS sign-out was statistically significant after implementation of reflex biomarker testing in NSCLC samples.
- 6 October 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (5) , 813-819
Implementation of a next-generation sequencing and PD-L1 immunohistochemistry reflex testing protocol for non–small cell lung cancers improves turnaround time
Objective: Targeted therapy in non–small cell lung cancer (NSCLC) is now often included as first-line treatment in the neoadjuvant and adjuvant settings. Delays in optimizing treatments based on biomarker status can affect outcomes. Therefore, we assessed the turnaround time (TAT) of reflex biomarker testing for all NSCLCs clinical stage 1B and greater. Methods: A next-generation sequencing (NGS) and PD-L1 immunohistochemistry reflex protocol for NSCLC clinical stage 1B and greater was implemented. Turnaround time intervals between procedure date, pathology sign-out, date received in the molecular laboratory, and date of NGS sign-out were calculated. Median and IQR of each interval before and after implementation of the reflex protocol were calculated and compared using the Mann-Whitney U test. Results: In total, 492 lung cancer NGS cases were identified, 351 before and 141 after implementation of the reflex protocol. The prereflex cases, after exclusion of biomarker testing ordered on older blocks and outside consults (n = 165), demonstrated a 22-day median time from procedure to NGS sign-out (range, 11-70 days; IQR, 9; mean, 24 days), compared to a 20-day median time (range, 13-54 days; IQR, 4.5; mean, 21 days) postimplementation (n = 120) (P < .000103). Conclusions: Reduction in median TAT from procedure to NGS sign-out was statistically significant after implementation of reflex biomarker testing in NSCLC samples.